Masimo Receives FDA Clearance for New Respiratory Monitoring Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Source: Newsfilter
- FDA Approval for New Feature: Masimo's Radius VSM® wearable monitor has received FDA 510(k) clearance for its opioid-induced respiratory depression (OIRD) detection capability, which will assist clinicians in identifying respiratory risks earlier, thereby enhancing patient safety within hospitals.
- Smart Sensor Application: This feature leverages Masimo's smartSET™ pulse oximetry sensor platform to analyze continuous physiological data, providing earlier clinical awareness that supports faster, more informed decisions when a patient's condition is rapidly deteriorating, significantly improving monitoring effectiveness.
- Enhanced Monitoring Capability: The introduction of the OIRD detection feature not only strengthens the monitoring capabilities of Radius VSM but also includes a visual alarm system that alerts clinicians to changes in patient condition, ensuring rapid response during critical situations and further improving care quality in hospitals.
- Future Development Potential: Masimo plans to develop additional pattern recognition algorithms for the smartSET platform, aiming to translate this technology into broader hospital monitoring solutions, thereby advancing the application of continuous monitoring technology across various care environments and enhancing overall patient care standards.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 177.170
Low
240.00
Averages
266.18
High
310.00
Current: 177.170
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Corporation Schedules Q2 2026 Earnings Conference Call
- Earnings Call Schedule: Danaher Corporation will hold its Q2 2026 earnings conference call on July 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Information: The call and accompanying slides will be webcast on the 'Investors' section of Danaher's website, enhancing transparency and allowing investors to access real-time information.
- Replay Availability: A replay of the conference call will be available shortly after the conclusion and will remain accessible until August 4, 2026, ensuring that investors who cannot attend live can still obtain key insights.
- Earnings Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, further enhancing investor understanding and engagement with the company's performance.
See More
Investment Opportunities in the Healthcare Sector
- Healthcare Spending Growth: U.S. healthcare spending is projected to reach nearly $5.3 trillion in 2024, indicating long-term growth potential in the sector, making stocks like CRISPR, Zoetis, and Danaher attractive for investors.
- CRISPR's Innovation Potential: CRISPR Therapeutics leads in gene editing, with its FDA-approved Casgevy treatment expected to boost sales from $36 million to $145 million, presenting a volatile yet promising long-term investment opportunity.
- Zoetis Market Rebound: Despite negative publicity from Librela, Zoetis trades at a low P/E of 11 compared to its historical average of 37, with analysts forecasting a 9% annual growth over the next three years, offering a compelling investment case.
- Danaher's Acquisition Strategy: Danaher recently acquired Masimo for $9.9 billion, enhancing its position in pulse oximetry technology; despite a 40% drop from its peak, the stock's future growth potential remains strong and appealing to investors.
See More
Masimo Receives FDA Clearance for New Respiratory Monitoring Technology
- FDA Approval for New Feature: Masimo's Radius VSM® wearable monitor has received FDA 510(k) clearance for its opioid-induced respiratory depression (OIRD) detection capability, which will assist clinicians in identifying respiratory risks earlier, thereby enhancing patient safety within hospitals.
- Smart Sensor Application: This feature leverages Masimo's smartSET™ pulse oximetry sensor platform to analyze continuous physiological data, providing earlier clinical awareness that supports faster, more informed decisions when a patient's condition is rapidly deteriorating, significantly improving monitoring effectiveness.
- Enhanced Monitoring Capability: The introduction of the OIRD detection feature not only strengthens the monitoring capabilities of Radius VSM but also includes a visual alarm system that alerts clinicians to changes in patient condition, ensuring rapid response during critical situations and further improving care quality in hospitals.
- Future Development Potential: Masimo plans to develop additional pattern recognition algorithms for the smartSET platform, aiming to translate this technology into broader hospital monitoring solutions, thereby advancing the application of continuous monitoring technology across various care environments and enhancing overall patient care standards.
See More
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Eaton Merges with Dana, Focuses on AI Data Center Growth
- Significant Deal Value: The merger between Dana and Eaton's Mobility business is valued at $5.1 billion, which not only removes a drag on Eaton's earnings growth but also positions the company to capitalize on higher-margin businesses supporting data center buildout, enhancing overall market competitiveness.
- Enhanced Growth Potential: Post-merger, Eaton's overall valuation will reach approximately $10 billion, and by leveraging both companies' technological strengths in vehicle propulsion systems, it is expected to boost Eaton's organic growth rate, further solidifying its market position in electrical equipment.
- Tax Structure Optimization: The transaction utilizes a Reverse Morris Trust structure, allowing Eaton to avoid substantial corporate taxes that would arise from a direct sale, with an anticipated cash distribution of around $1.1 billion to be used for debt repayment or other growth investments, thereby enhancing financial flexibility.
- Positive Market Reaction: Eaton's stock rose over 4% following the merger announcement, currently trading around $391, with analysts generally viewing this transaction as a catalyst for Eaton to accelerate its focus on core higher-growth, higher-margin Electrical and Aerospace businesses, boosting investor confidence.
See More
U.S. Stocks Rise on Semiconductor Rebound Amid Geopolitical Tensions
- Market Rebound: U.S. stocks rose on Thursday, driven by a rebound in semiconductor stocks, with the Dow Jones Industrial Average gaining approximately 341 points, or 0.67%, while the S&P 500 and Nasdaq Composite increased by 0.38% and 0.52%, respectively, demonstrating market resilience amid geopolitical tensions.
- SpaceX IPO Outlook: Wall Street analysts initiated coverage on SpaceX, with New Street Research assigning a $165 price target and Oppenheimer setting a $190 target, as Jim noted that the IPO is likely to have a significant impact on broader market trading, potentially influencing market dynamics for the next month.
- Honeywell Investor Day: Ahead of its planned breakup into aerospace and automation businesses on June 29, Honeywell held an investor day, where Jim expressed optimism about the long-term value creation potential of the automation segment, arguing that the market is underestimating this opportunity, with a potential upside of 50 points post-restructuring.
- Rapid Stock Review: At the end of the video, Jim highlighted stocks including Oracle, Danaher, and Kontoor Brands, indicating ongoing investor interest and potential investment opportunities in these companies.
See More
Danaher Corporation Schedules Q2 2026 Earnings Conference Call
- Earnings Call Schedule: Danaher Corporation will hold its Q2 2026 earnings conference call on July 21, 2026, at 8:00 a.m. ET, lasting approximately one hour, during which the company will discuss its financial performance and future expectations.
- Webcast Information: The call and accompanying slides will be webcast on the 'Investors' section of Danaher's website, enhancing transparency and allowing investors to access real-time information.
- Replay Availability: A replay of the conference call will be available shortly after the conclusion and will remain accessible until August 4, 2026, ensuring that investors who cannot attend live can still obtain key insights.
- Earnings Materials Release: Danaher will post its earnings press release and related materials at 6:00 a.m. on the day of the call, further enhancing investor understanding and engagement with the company's performance.
See More
Investment Opportunities in the Healthcare Sector
- Healthcare Spending Growth: U.S. healthcare spending is projected to reach nearly $5.3 trillion in 2024, indicating long-term growth potential in the sector, making stocks like CRISPR, Zoetis, and Danaher attractive for investors.
- CRISPR's Innovation Potential: CRISPR Therapeutics leads in gene editing, with its FDA-approved Casgevy treatment expected to boost sales from $36 million to $145 million, presenting a volatile yet promising long-term investment opportunity.
- Zoetis Market Rebound: Despite negative publicity from Librela, Zoetis trades at a low P/E of 11 compared to its historical average of 37, with analysts forecasting a 9% annual growth over the next three years, offering a compelling investment case.
- Danaher's Acquisition Strategy: Danaher recently acquired Masimo for $9.9 billion, enhancing its position in pulse oximetry technology; despite a 40% drop from its peak, the stock's future growth potential remains strong and appealing to investors.
See More
Masimo Receives FDA Clearance for New Respiratory Monitoring Technology
- FDA Approval for New Feature: Masimo's Radius VSM® wearable monitor has received FDA 510(k) clearance for its opioid-induced respiratory depression (OIRD) detection capability, which will assist clinicians in identifying respiratory risks earlier, thereby enhancing patient safety within hospitals.
- Smart Sensor Application: This feature leverages Masimo's smartSET™ pulse oximetry sensor platform to analyze continuous physiological data, providing earlier clinical awareness that supports faster, more informed decisions when a patient's condition is rapidly deteriorating, significantly improving monitoring effectiveness.
- Enhanced Monitoring Capability: The introduction of the OIRD detection feature not only strengthens the monitoring capabilities of Radius VSM but also includes a visual alarm system that alerts clinicians to changes in patient condition, ensuring rapid response during critical situations and further improving care quality in hospitals.
- Future Development Potential: Masimo plans to develop additional pattern recognition algorithms for the smartSET platform, aiming to translate this technology into broader hospital monitoring solutions, thereby advancing the application of continuous monitoring technology across various care environments and enhancing overall patient care standards.
See More
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Eaton Merges with Dana, Focuses on AI Data Center Growth
- Significant Deal Value: The merger between Dana and Eaton's Mobility business is valued at $5.1 billion, which not only removes a drag on Eaton's earnings growth but also positions the company to capitalize on higher-margin businesses supporting data center buildout, enhancing overall market competitiveness.
- Enhanced Growth Potential: Post-merger, Eaton's overall valuation will reach approximately $10 billion, and by leveraging both companies' technological strengths in vehicle propulsion systems, it is expected to boost Eaton's organic growth rate, further solidifying its market position in electrical equipment.
- Tax Structure Optimization: The transaction utilizes a Reverse Morris Trust structure, allowing Eaton to avoid substantial corporate taxes that would arise from a direct sale, with an anticipated cash distribution of around $1.1 billion to be used for debt repayment or other growth investments, thereby enhancing financial flexibility.
- Positive Market Reaction: Eaton's stock rose over 4% following the merger announcement, currently trading around $391, with analysts generally viewing this transaction as a catalyst for Eaton to accelerate its focus on core higher-growth, higher-margin Electrical and Aerospace businesses, boosting investor confidence.
See More
U.S. Stocks Rise on Semiconductor Rebound Amid Geopolitical Tensions
- Market Rebound: U.S. stocks rose on Thursday, driven by a rebound in semiconductor stocks, with the Dow Jones Industrial Average gaining approximately 341 points, or 0.67%, while the S&P 500 and Nasdaq Composite increased by 0.38% and 0.52%, respectively, demonstrating market resilience amid geopolitical tensions.
- SpaceX IPO Outlook: Wall Street analysts initiated coverage on SpaceX, with New Street Research assigning a $165 price target and Oppenheimer setting a $190 target, as Jim noted that the IPO is likely to have a significant impact on broader market trading, potentially influencing market dynamics for the next month.
- Honeywell Investor Day: Ahead of its planned breakup into aerospace and automation businesses on June 29, Honeywell held an investor day, where Jim expressed optimism about the long-term value creation potential of the automation segment, arguing that the market is underestimating this opportunity, with a potential upside of 50 points post-restructuring.
- Rapid Stock Review: At the end of the video, Jim highlighted stocks including Oracle, Danaher, and Kontoor Brands, indicating ongoing investor interest and potential investment opportunities in these companies.
See More
